An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma

Female who was or intended to become pregnant during the study or within 12 weeks after study completion

Nursing, or intended to be nursing during the study or within 12 months after study completion

Taking medications prohibited during the study or had not complied with the requirements for the designated washout periods for any of the prohibited medications

Anatomical abnormalities of the nose (turbinate hypertrophy, septal deviation, polyps)

Acute or chronic sinusitis currently being treated with antibiotics and/or topical or oral decongestants

Rhinitis medicamentosa

Evidence of persistent asthma, or asthma with daytime and nighttime symptoms not controlled by short-acting beta2-adrenoceptor agonists

Asthma requiring chronic use of inhaled or systemic corticosteroids

Upper respiratory tract or sinus infection that required antibiotic therapy and had not had at least a 14-day wash-out period prior to the run-in period, or had a viral upper respiratory infection within 7 days prior to screening

Dependence on nasal, oral or ocular decongestants, nasal topical antihistamines, or nasal steroids

Undergoing a progressive course of immunotherapy (hyposensitization). Subjects on a regular maintenance schedule prior to the screening visit were eligible for study inclusion; however, subject could not receive hyposensitization treatment within 24 hours prior to any study visit

Diagnosed of cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas)

Concomitant medical problem

Had any of the following clinical conditions: active or quiescent tuberculosis infection of the respiratory tract, untreated fungal, bacterial, systemic viral infections or ocular herpes simplex

Smoked or had smoked within the previous 6 months

Member of the staff, affiliated with, or family member of the staff personnel directly involved with this study

Previously randomized into this study

Any other clinically significant deviation from normal in the physical examination or medical history that could interfere with the study evaluation or affect subject safety

In a situation or condition that could interfere with participation in the study

Used any drug or device in an investigational protocol in the 30 days prior to visit 1

Participating in other clinical studies

Allergic or has sensitivity to the study drug or its excipients

Compromised ability to provide informed consent

History of non-compliance with medication or treatment protocols

What this study is about